Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Cdk4 CRISPR/Cas9 KO Plasmid (h): sc-400148
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Cdk4 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Cdk4 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Cdk4 Antibody (DCS-35): sc-23896
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cdk4 CRISPR/Cas9 KO Plasmid (h) | sc-400148 | 20 µg | $397.00 |
Overview
CDK4 encodes cyclin-dependent kinase 4 (Cdk4), a core regulator of the G1 phase that partners with D-type cyclins to phosphorylate RB family proteins and promote E2F-dependent transcription required for S-phase entry. Cdk4 activity is controlled by mitogenic signaling and CDK inhibitors such as CDKN2A/p16, integrating inputs from MAPK/ERK and PI3K–AKT pathways into cell-cycle commitment. Dysregulation of the CDK4–cyclin D–RB axis is frequently associated with aberrant proliferation and altered checkpoint control across tumor and developmental biology contexts. As a nodal cell-cycle kinase, CDK4 is routinely studied for its roles in proliferation, senescence, lineage specification, and stress responses.
Cdk4 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CDK4 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CDK4 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CDK4 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Cdk4 protein expression.
This CRISPR knockout system enables efficient generation of CDK4-deficient cell models for investigation of Cdk4 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CDK4 exon(s) critical for Cdk4 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CDK4 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Cdk4 CRISPR/Cas9 KO Plasmid (h) and Cdk4 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CDK4 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Cdk4 HDR Plasmid (h) and Cdk4 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CDK4 homology arms to support homology-directed repair at defined CDK4 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.